History

Group revenue increased by 28% to R1,080 billion
Normalised HEPS and EPS increased by 31% to 35,0 cents

Cipla Medpro ranked 3rd largest local pharmaceutical company by value (IMS, June 2012)

Cipla Medpro is the fastest growing of the top 10 local pharmaceutical companies by value (IMS, June 2012)
Interim dividend of 8,5 cents (2011: 6,5 cents) per share

Launch of Cipla Nutrition range

Group revenue increased by 22% to R1,768 billion
HEPS and EPS increased by 43% to 63,1 cents
Final dividend of 7,5 cents per share (total dividend for the year of 14,0 cents per share)

Completed share buy-back of 1,7% of ordinary shares at a total cost of R50 million

Launch of oncology division

Group revenue increased by 18% to R842,8 million (for the six month period)
Interim dividend of 6,5 cents per share
Cipla Medpro ranked 3rd largest local pharmaceutical company by value

Animal health company, Cipla Agrimed (Pty) Limited, awarded a significant portion (R100 million over 2 years) of the national tender RT12-2011

Group awarded 15% (R633 million over 2 years) of the ARV tender RT71-2010
Fastest growing pharmaceutical company, of the top 10 pharmaceutical companies in South Africa
Group revenue up 15% to R1,447 billion and EPS up 22% to 44,2 cents
Final dividend of 6 cents per share (total dividend for the year of 11 cents per share)

President Jacob Zuma officially opened the manufacturing facility in Durban, KwaZulu-Natal

Declaration of its inaugural interim dividend of 5 cents per share
Group revenue up 29% to R714,3 million (for the six month period)

Group revenue up 27% to R1,262 billion and EPS up 24% to 36,3 cents
Cipla Medpro retains its position as 4th largest pharmaceutical company by value

Cipla Medpro division revenue up 24% (for the six month period)

Cipla Medpro ranked 4th largest local pharmaceutical company by value

Revenue from continuing operations increased by 23,4% to R994,9 million and profit after tax by 22,2% to R130,9 million.

Cipla Medpro South Africa Limited replaces Enaleni Pharmaceuticals Limited as group name. Group to trade on JSE under abbreviation 'CIPLAMED' and share code 'CMP'.

Cipla Medpro Manufacturing receives MCC-approval to proceed with multi-product manufacturing in the Durban-based manufacturing facility as it nears the final stages of its R195-million upgrade to international PIC/S compliance.

Mid-year results saw revenue (continuing operations) increase 15% to R463 million (for the six month period) and a total debt reduction of R76,9 million.

Year end results saw revenues increase 19 % to R940,7 million, and profit after taxation increase 27% to R131,8 million. Cipla Medpro retains its position as 6th largest pharmaceutical company.

Enaleni concludes the disposal of its Bioharmony and Muscle Science nutraceutical and sports nutrition brands for R26,8 million.

Enaleni concludes disposal of its Enaleni Pharmaceuticals Consumer Division to India's Marico Limited for R92,8 million.

Cipla Medpro CEO Jerome Smith is appointed Enaleni Group CEO

The Enaleni board of directors, under advisement from Jerome Smith, elects to strategically focus the business on pharmaceuticals and announces plans to divest of the group's consumer division businesses.

After a successful capital raising exercise to raise R125 million, work commences on upgrading the 10 000m2 manufacturing facility to international PIC/S standards. Completion date set for mid-2008.

Enaleni rated the Most Empowered JSE-listed company in a Financial Mail / Empowerdex survey.

Year end results see revenues trebled to R789 million and PBIT increased sevenfold to R190 million.

Enaleni consolidates previous year's acquisitions within its Pharmaceutical and Consumer Divisions.

Group results for the year ended 31 December 2005 see revenues increase by 113% to R245 million and PBIT increased by 364 % to R24,9 million.

Enaleni ranked as a top ten South African pharmaceutical company.

Enaleni becomes the first company to move from Alt X to the JSE Main Board

Enaleni undertakes one of the largest pharmaceutical deals ever recorded in South Africa with the R1,5 billion acquisition of Cipla Medpro, one of SA's leading generic medicines businesses.

Enaleni acquires FirstPharm Pharmaceuticals, a generic and Over the Counter medicines business for R32 million.

Enaleni lists on the Johannesburg Securities Exchange (JSE) Alt-X division

Through strategic acquisitions including Bioharmony, Muscle Science, Modex Cosmetics, Zedchem and Kamillen, Enaleni expands into the nutraceutical and personal care markets.

Enaleni Pharmaceuticals is born from a management buy-out of Reckitt-Benckiser SA's (RBSA) Durban manufacturing plant. The company, with 6 management and 76 staff members, tenders for and wins the RBSA manufacturing contract. Further manufacturing contracts for multinational and local companies such as Merck Generics, Unilever and Huletts follow.